主页 > 医学信息 >
【medical-news】利塞膦酸盐可以阻止乳腺癌患者的
2/7/2007
By: Reuters Health
NEW YORK (Reuters Health), Feb 7 - Once-weekly treatment with risedronate prevents bone loss in breast cancer survivors who underwent chemotherapy, according to the results of a new study, suggesting that early bisphosphonate treatment be considered for these patients。
Previous research has shown bone loss and fractures in women with chemotherapy-induced early menopause, the authors explain, but few studies have examined prevention of chemotherapy-induced bone loss.
Dr. Susan L. Greenspan from University of Pittsburgh, Pennsylvania, and other members of the Risedronate's Effect on Bone Loss in Breast Cancer (ReBBeCa) Study investigated the effects of risedronate, 35 mg once weekly, on bone mass in 87 newly postmenopausal women with breast cancer who finished chemotherapy (with or without tamoxifen or aromatase inhibitors).
The findings are published in the January issue of the Journal of Clinical Endocrinology & Metabolism.
Bone mineral density (BMD) in the spine increased by 1.2% after one year of treatment with risedronate, the authors report, but BMD in the spine decreased by 0.9% in the placebo group. Results were similar for BMD for the total hip. BMD remained stable in the distal radius and total body among risedronate-treated women, the results indicate, but both decreased in the placebo group.
The changes did not differ significantly between women taking tamoxifen and women not taking tamoxifen, the researchers note. Markers of bone formation and resorption decreased significantly in the treatment group compared with the placebo group, the report indicates.
Adverse events did not differ significantly between the risedronate and placebo groups, the investigators say.
"These results have important clinical ramifications for breast cancer survivors who go into remission after early, aggressive therapy," the authors conclude. "Because of the long-term survival of this cohort, they are at risk for bone loss and osteoporosis. Skeletal integrity needs to be assessed and considered as part of their long-term management."
"The ReBBeCa study provides evidence that bisphosphonate therapy is likely to be useful in preventing chemotherapy-induced bone loss," writes Dr. Richard Eastell from University of Sheffield, U.K., in a related editorial.
The results of ongoing studies "should inform us whether bisphosphonates can be used to prevent bone loss due to aromatase inhibitors," he added.
Last Updated: 2007-02-07 11:03:06 -0400 (Reuters Health)
J Clin Endocrinol Metab 2007;92:42-43,131-136.
http://www.auntminnie.com/index.asp?Sec=sup&Sub=wom&Pag=dis&ItemId=74542&wf=1 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 初译：
Risedronate prevents bone loss in breast cancer survivors
利塞膦酸盐可以阻止乳腺癌患者的骨盐丢失
NEW YORK (Reuters Health), Feb 7 - Once-weekly treatment with risedronate prevents bone loss in breast cancer survivors who underwent chemotherapy, according to the results of a new study, suggesting that early bisphosphonate treatment be considered for these patients。
纽约（路透社健康专栏），2月7日－根据一项最新研究结果，乳腺癌患者在结束化疗后，每周使用一次利塞膦酸盐可以预防骨盐丢失，这表明可及早考虑对该类患者施行二膦酸盐类药物疗法。
Previous research has shown bone loss and fractures in women with chemotherapy-induced early menopause, the authors explain, but few studies have examined prevention of chemotherapy-induced bone loss.
研究报告作者解释说，既往研究发现，化疗可引起妇女绝经期提前及其骨盐丢失和骨折，但却很少有人就如何预防化疗所致的骨盐丢失做过研究。
Dr. Susan L. Greenspan from University of Pittsburgh, Pennsylvania, and other members of the Risedronate's Effect on Bone Loss in Breast Cancer (ReBBeCa) Study investigated the effects of risedronate, 35 mg once weekly, on bone mass in 87 newly postmenopausal women with breast cancer who finished chemotherapy (with or without tamoxifen or aromatase inhibitors).
来自宾夕法尼亚州匹兹堡大学的苏珊.L.格林斯潘博士和利塞膦酸盐之于乳腺癌患者骨盐丢失疗效(ReBBeCa)研究组织的成员就使用利塞膦酸盐（35 mg/周）对骨量的影响进行了研究。研究对象为87位结束化疗的刚刚停经的乳腺癌患者，这些患者在治疗期间有的使用它莫西芬或芳香酶抑制剂，有的则没有。
The findings are published in the January issue of the Journal of Clinical Endocrinology & Metabolism.
研究结果发表于1月份出版的《临床内分泌学&新陈代谢杂志》。
Bone mineral density (BMD) in the spine increased by 1.2% after one year of treatment with risedronate, the authors report, but BMD in the spine decreased by 0.9% in the placebo group. Results were similar for BMD for the total hip. BMD remained stable in the distal radius and total body among risedronate-treated women, the results indicate, but both decreased in the placebo group.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-31 05:15
医学,生命科学网